Dr. Gennaro Pagano discusses the findings of the post-hoc analysis of the PASADENA trial, a study using the monoclonal antibody Prasinezumab directed at aggregated α-synuclein, where motor progression trajectories differed between active and placebo groups. Read article » ([ Ссылка ])
